A 52-year-old man from Delhi presents with a 3-month history of progressive jaundice, pale stools, and dark urine. On examination, he has hepatomegaly and a palpable gallbladder. Abdominal ultrasound shows a 4 cm hypoechoic lesion in the pancreatic head with dilated intrahepatic bile ducts. Serum bilirubin is 8.2 mg/dL (direct 6.8 mg/dL), and alkaline phosphatase is markedly elevated. His serum CA 19-9 level is 320 U/mL (normal <37 U/mL). Which statement best describes the clinical utility of CA 19-9 in this patient?

Explanation

## Clinical Context This patient presents with classic features of pancreatic head cancer: painless obstructive jaundice, hepatomegaly, imaging evidence of a pancreatic mass, and markedly elevated CA 19-9. ## CA 19-9: Role and Limitations **Key Point:** CA 19-9 is a tumor-associated carbohydrate antigen (Lewis antigen) that is elevated in pancreatic cancer but lacks diagnostic specificity and sensitivity for initial diagnosis. ### Appropriate Clinical Uses 1. **Prognostic indicator** — elevated preoperative CA 19-9 correlates with advanced disease and poor prognosis 2. **Monitoring treatment response** — serial measurements during chemotherapy or post-resection surveillance 3. **Detecting recurrence** — rising CA 19-9 after resection suggests recurrent disease 4. **Supportive evidence** — in the context of imaging and clinical findings, supports suspicion of malignancy ### Why NOT Diagnostic Alone - **Sensitivity:** 80–85% in advanced disease, but only 50% in early-stage cancer - **Specificity:** ~90%, but elevated in benign conditions (pancreatitis, cirrhosis, cholangitis, gastric/biliary cancers) - **Cannot replace tissue diagnosis** — histopathology or cytology is required for definitive diagnosis **High-Yield:** CA 19-9 is useful for **monitoring** and **prognostication**, not for **diagnosis**. ## Diagnostic Algorithm for Pancreatic Cancer ```mermaid flowchart TD A[Imaging: mass in pancreatic head]:::outcome --> B{Tissue diagnosis needed?}:::decision B -->|Yes| C[EUS-FNA or ERCP-guided biopsy]:::action C --> D[Histopathology confirms malignancy]:::outcome D --> E[Baseline CA 19-9 + staging]:::action E --> F[Treatment planning]:::action F --> G[Serial CA 19-9 monitoring]:::action ``` **Clinical Pearl:** In a patient with imaging findings highly suggestive of pancreatic cancer, tissue confirmation is still the gold standard before initiating chemotherapy or surgery. CA 19-9 supports the clinical suspicion but cannot substitute for histology.